CA3033827A1 — Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl )-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide,preparation, and uses thereof
Assigned to BeOne Medicines I GmbH · Expires 2018-02-22 · 8y expired
What this patent protects
The present invention relates to a crystalline form of (S)-7-(l-acryloylpiperidin-4-yl)-2-(4- phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[l,5-a]pyrimidine-3-carboxamide for inhibiting Btk, methods of preparation thereof and pharmaceutical compositions, and use of the crystalline f…
USPTO Abstract
The present invention relates to a crystalline form of (S)-7-(l-acryloylpiperidin-4-yl)-2-(4- phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[l,5-a]pyrimidine-3-carboxamide for inhibiting Btk, methods of preparation thereof and pharmaceutical compositions, and use of the crystalline form above in the treatment of a disease, or in the manufacturing of a medicament for the treatment of a disease.
Drugs covered by this patent
- Imbruvica (ibrutinib) · AbbVie
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.